SGI
IBB icon

Summit Global Investments’s iShares Biotechnology ETF IBB Stock Holding History

Summit Global Investments’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$896K Buy
4,712
+1,241
+36% +$213K 0.05% 227
2026
Q1 		$586K Buy
+3,471
New +$594K 0.03% 304

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Summit Global Investments's IBB Position: Q2 2026 in Review

Summit Global Investments increased its iShares Biotechnology ETF (IBB) stake by 36% in Q2 2026, buying an estimated $213K and bringing the position to 4,712 shares worth $896K. The position accounts for 0.05% of the portfolio, ranked #227.

Summit Global Investments first reported a position in IBB in Q1 2026 and has held it in 2 quarters since. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • Summit Global Investments held 4,712 shares of iShares Biotechnology ETF worth $896K as of Q2 2026.
  • Summit Global Investments bought 1,241 iShares Biotechnology ETF shares in Q2 2026, an estimated $213K.
  • iShares Biotechnology ETF made up 0.05% of Summit Global Investments's portfolio in Q2 2026, its #227 holding.
  • Summit Global Investments first reported a position in iShares Biotechnology ETF in Q1 2026 and has held it in 2 quarters since.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Summit Global Investments's 13F filing for Q2 2026, filed 3 Aug 2026.